

Fax Referral To: 1-877-232-5455 Address: 500 Ala Moana Blvd., Bldg 1 Honolulu, HI 96813

Six Simple Steps to Submitting a Referral **PATIENT INFORMATION** (Complete or include demographic sheet) _____ DOB: _____ Gender: 🗌 Male 🔲 Female City, State, ZIP Code: Address: Preferred Contact Methods: Phone (to primary # provided below) Text (to cell # provided below) Email (to email provided below) Note: Carrier charges may apply. By providing the phone number(s) and email address above, you are consenting to receive automated calls, emails and/or text messages from CVS Specialty® about your prescription(s), account, and health care. Standard data rates apply. Message frequency varies. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone. _____ Alternate Phone: __ Primary Phone: ___ _____ Last Four of SSN: _____ Primary Language: ______ Email: Parent/Caregiver/Legal Guardian Name (Last, First): ______Relationship to patient: _____ 2 PRESCRIBER INFORMATION Prescriber's Name: ___ _____ State License #: _______ Prescriber's Name: ______ Broup or Hospital: ____ Group or Hospital: ____ _____ City, State, ZIP Code: ______ Fax____ Contact Person: _____ Contact's Phone: _____ Address: _____ Phone: INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back) Is the Patient Insured? ☐ Yes ☐ No Is the Patient enrolled or eligible for Medicare/Medicaid? ☐ Yes ☐ No Policy Holder's Name:______ Policy Holder's DOB:_____ Relationship to Patient:_____ Medical Insurance: _____ Telephone: _____ Policy ID: _____ Group #: _____ ☐ Check box if patient is enrolled in manufacturer copay assistance If yes, please provide ID# _____ 4 DIAGNOSIS AND CLINICAL INFORMATION Needs by Date:___ Ship to: Patient Office Other: Diagnosis (ICD-10): M06.9 Rheumatoid Arthritis, Unspecified M45.9 Non-Radiographic Axial Spondylarthritis (nr-axSpA) ☐ M45.A0 Ankylosing Spondylitis of Unspecified Sites in Spine L40.50 Arthropathic Psoriasis, Unspecified L40.59 Other Psoriatic Arthropathy M08.00 Unspecified Juvenile Rheumatoid Arthritis of Unspecified Site M08.90 Polyarticular Juvenile Idiopathic Arthritis (PJIA) M08.20 Systemic Juvenile Idiopathic Arthritis (SJIA) M31.6 Giant Cell Arteritis (GCA) Other Code: _____ Description _____ **Patient Clinical Information:** Allergies: Prior therapy, treatment dates, and reason(s) for discontinuation: Treatment status: New to therapy Continuation of therapy; date of last treatment // Needs by date: _lb/kg Height:_____In/cm TB Test Result:_____ Date:___ Weight: **Nursing and Administration:** First dose administration of monoclonal antibodies (mABs) should be administered in a controlled setting (may vary depending upon medication specific policy). For Remicade/Remicade Biosimilars, the first dose must be administered in a controlled setting. Specialty pharmacy to coordinate home health Infusion nurse visit as necessary? Tyes No Site of Care: 🔲 Home Infusion* 🔲 Coram Ambulatory Infusion Suite (AIS)* 🔲 Prescriber's Office** 🔲 Other Infusion Clinic

*Home Infusion/Coram AIS: Diluents, Flushes, Supplies, Nursing Services for drug administration/therapy teach train.

**Prescriber's Office/Other Infusion Clinic: Drug only for facility administration

Phone: 1-808-254-2727

NCPDP: 1203417

	Please Con	nplete Patient, Prescriber	and Patient Clinical Information		
	Patient DOB: Patient Phone:				
			Prescriber Phone:		
Patient Clinical Ir Allergies:					
Meight:	lh/ka Heial	ht: In/cm	TB Test Result:	Date:	
DRESCRIPTI	ION INFORMATIO	N	TO TOSE NOSCIE.	<u> </u>	
	STRENGTH		E & DIRECTIONS	QUANTITY/REFILLS	
Actemra	☐ 80 mg/4 mL ☐ 200 mg/10 mL ☐ 400 mg/20 mL	☐ Induction Dose: Infuse 4 r ☐ Maintenance Dose: Infuse ☐ Other:	mg/kg every 4 weeks.	Quantity: Refills:	
☐ Avsola	100 mg vial	 Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 6 weeks thereafter Ankylosing Spondylitis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 6 weeks Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Rheumatoid Arthritis Induction Dose: Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Rheumatoid Arthritis Maintenance Dose: Infuse IV at 3-10 mg/kg (Dose =mg) every 4, 6 or 8 weeks (circle one) Other: 		Quantity: # of 100 mg vial(s) Refills:	
☐ Inflectra ☐ Infliximab	100 mg vial	Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 6 weeks thereafter Ankylosing Spondylitis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 6 weeks Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Rheumatoid Arthritis Induction Dose: Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Rheumatoid Arthritis Maintenance Dose: Infuse IV at 3-10 mg/kg (Dose =mg) every 4, 6 or 8 weeks (circle one) Other:		Quantity: # of 100 mg vial(s) Refills: 	
	patient support programs	STAMP SIGNATURE NOT		vided as needed for administratio	
	6 PRESCRIBER SI	GNATURE REQUIRED (S	STAMP SIGNATURE NOT ALLOW	(ED)	
•		/ Do Not Substitute / No Substitution /	May Substitute / Product Selection Permitted / Substitution Permissible		
DAW / May Not Substitute Prescriber's Signature:Date:		Date:	Prescriber's Signature:	Date:	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

otiont Name:		lete Patient, Prescriber and Patient Clinical Information				
	Patient DOB: Patient Phone:					
		Prescriber Phone:				
atient Clinical						
eight:	lb/kg Height:	In/cm TB Test Result:	Date:			
	TION INFORMATION					
	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS			
Orencia	250 mg vial	☐ Infuse mg at weeks 0, 2 and 4, then every 4 weeks thereafter. ☐ Other:	Quantity: Refills:			
Remicade Renflexis	100 mg vial	Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 6 weeks thereafter Ankylosing Spondylitis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 6 weeks Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Rheumatoid Arthritis Induction Dose: Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Rheumatoid Arthritis Maintenance Dose: Infuse IV at 3-10 mg/kg (Dose =mg) every 4, 6 or 8 weeks (circle one) Other:mg) every 4, 6 or 8 weeks (circle one)	Quantity: # of 100 mg vial(s) Refills:			
Riabni Rituxan Ruxience	☐ 100 mg/10 mL vial ☐ 500 mg/50 mL vial	☐ Infuse two doses of 1000 mg separated by 2 weeks. ☐ Other:	Quantity: Refills:			
Simponi ARIA	50 mg/4 mL in a single use vial	Adult patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: Infuse 2 mg/kg over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter. Pediatric patients with polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: 80 mg/m2 intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter Other:	Quantity: # of 50 mg vial Refills:			
Patient is interested	in patient support programs PRESCRIBER SIG	STAMP SIGNATURE NOT ALLOWED Ancillary supplies and kits prov NATURE REQUIRED (STAMP SIGNATURE NOT ALLOW				
"Dispense As Writte DAW / May Not Sub Prescriber's Si		o Not Substitute / No Substitution / May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:	Date:			

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

			nd Patient Clinical Information		
		Patient DOB:	Patient Phone:		
	:				
Prescriber Name	e:	P	rescriber Phone:		
Patient Clinical	Information:				
Allergies:					
			B Test Result:	Date:	
PRESCRIP	TION INFORMATION				
MEDICATION	STRENGTH	DOS	E & DIRECTIONS	QUANTITY/REFILLS	
Truxima	☐ 100 mg/10 mL vial ☐ 500 mg/50 mL vial		O mg separated by 2 weeks	Quantity: Refills:	
☐ Tyenne (tocilizumab-	80 mg/4 mL vial 200 mg/10 mL vial 400 mg/20 mL vial	RA Induction Dose: Infus weeks RA Maintenance Dose: I	se 4 mg per kg (mg) IV every 4 nfuse 8 mg per kg (mg) IV every 4		
			Infuse 6 mg per kg (mg) IV every 4		
		weeks (doses exceeding 600 mg per infusion are not recommended) PJIA Dose (> 2 years old weighing < 30 kg): Infuse 10 mg per		vials)	
aazg)		kg (mg) IV every 4 weeks		(# of 400 mg	
G,		<u> </u>	d weighing <u>></u> 30 kg): Infuse 8 mg per kg	vials) Refills:	
		SJIA Dose (≥ 2 years old kg (mg) IV every 2 wee	d weighing < 30 kg): Infuse 12 mg per ks		
		SJIA Dose (≥ 2 years old weighing ≥ 30 kg): Infuse 8 mg per kg(mg) IV every 2 weeksOther:			
Other	Strength:			Quantity:Refills:	
	6 PRESCRIBER SIG	NATURE REQUIRED (S	TAMP SIGNATURE NOT ALLOY	VED)	
DAW / May Not Sub			May Substitute / Product Selection Permitted / Substitution Permissible		
Prescriber's Si	ignature:	Date:	Prescriber's Signature:	Date:	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Rheumatology IV Enrollment Form Nursing Orders

Patient Address:		Patient DOR ¹		
			Patient Phone: _	
Irogarihar Namas			receriber Dhone:	
Prescriber Name: Patient Clinical Informa		Pr	rescriber Phone:	
	tion:			
.llergies: Veight:	lh/ka Haiaht	In/om TE	B Test Result:	Doto:
DDECODIDATION IN	_tb/kg = neight.		rest result.	Date:
PRESCRIPTION	NFORMATION	**ITEMS BELOW THIS LINE WIL	L ONLY BE SENT FOR INFUSIONS DONE	
MEDICATION/SUPPLIES	ROUTE		NGTH/ DIRECTIONS	QUANTITY/REFILLS
Catheter: PIV PORT CVC/PICC	IV	maintain IV access and paten PIV: NS 5 mL (Heparin 10 units	s/mL 3-5 mL if multiple days) eparin 10 units/mL or 100 units/mL access PORT w/ huber needle	Quantity: Refills:
Hydration: ☐ NS ☐ D5W	IV	Pre:	☐Other: 000 mL ☐ Other: ☐Other:	Hydration max infusion rate mL/hr (Adult max rate 250 mL/hr unless otherwise indicated)
☐Epinephrine **nursing requires**	□ IM □ SC	☐ 1:1000, 0.3mg/0.3 mL (gre☐ 1:2000, 0.15mg/0.3 mL (15☐ 1:1000, 0.1 mg/kg, Max 0.3 Mild-Moderate Reactions. Mafor severe allergic reaction, al	5-30 kg/33-66 lbs) Bmg (under 15kg) ay repeat in 3-5 minutes as needed	Quantity: Refills:
☐ Diphenhydramine Oral	PO	Premedication: 12.5 mg/kg (0-30 kg) 25 mg 50 mg (Over 30 kg)		Quantity: Refills:
Diphenhydramine 50 mg/mL vial **nursing required**	☐ Slow IV	1 mg/kg (under 15 kg) 12.5 mg-50 mg (15-30 kg) 25 mg-50 mg (Over 30 kg) If mild/moderate reaction: may repeat in 3-5 minutes as needed (Adult max dose: 100 mg/day) If severe allergic reaction: call 911		Quantity: Refills:
☐ Flush Orders:	Peripheral Access Central Venous Access	☐ 10 mL NS post flush ☐ 50 mL NS post flush to clear medication from tubing (recommended if no post-hydration) ☐ Other:		Send quantity sufficient for medication days supply
Additional Medication:				
Patient is interested in patient sup		STAMP SIGNATURE NOT ALLOWED NATURE REQUIRED (ST	Ancillary supplies and kits TAMP SIGNATURE NOT ALLO	provided as needed for administrati
DAW / May Not Substitute		o Not Substitute / No Substitution / Date:	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:	Date:

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.